Inclusion body myositis - a case based clinicopathological update

• Authors: Levente Bodoki , Melinda Vincze , Zoltán Griger , Tamás Csonka , Balázs Murnyák , Andrea Kurucz , Katalin Dankó , Tibor Hortobágyi
• Languages of publication: EN

Abstracts

EN

Inclusion body myositis is a slowly progressive myopathy affecting predominantly the middle-aged and older patient population. It is a major form of the idiopathic inflammatory myopathies which are chronic systemic autoimmune diseases characterized by symmetrical proximal muscle weakness. Unfortunately, there is no effective therapy yet; however, the early diagnosis is essential to provide treatment options which may significantly slow the progression of the disease. In our case-based clinicopathological study the importance of the close collaboration between the clinician and the neuropathologist is emphasised.

Keywords

EN

Idiopathic inflammatory myopathies; Inclusion body myositis (IBM); Amyloid-; Hyperphosphorylated tau; p62; TDP-43; IBMPFD

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2014
• Volume: 9
• Issue: 1
• Pages: 80-85

Dates

published

1 - 2 - 2014

online

4 - 2 - 2014

Contributors

author

Levente Bodoki

• Institute of Internal Medicine, Third Department of Internal Medicine, Division of Clinical Immunology, University of Debrecen Medical & Health Science Centre, Debrecen, Hungary

author

Melinda Vincze

• Institute of Internal Medicine, Third Department of Internal Medicine, Division of Clinical Immunology, University of Debrecen Medical & Health Science Centre, Debrecen, Hungary

author

Zoltán Griger

• Institute of Internal Medicine, Third Department of Internal Medicine, Division of Clinical Immunology, University of Debrecen Medical & Health Science Centre, Debrecen, Hungary

author

Tamás Csonka

• Institute of Pathology, Department of Neuropathology, University of Debrecen Medical and Health Science Centre, Debrecen, Hungary

author

Balázs Murnyák

• Institute of Pathology, Department of Neuropathology, University of Debrecen Medical and Health Science Centre, Debrecen, Hungary

author

Andrea Kurucz

• Institute of Pathology, Department of Neuropathology, University of Debrecen Medical and Health Science Centre, Debrecen, Hungary

author

Katalin Dankó

• Institute of Internal Medicine, Third Department of Internal Medicine, Division of Clinical Immunology, University of Debrecen Medical & Health Science Centre, Debrecen, Hungary

author

Tibor Hortobágyi

• Institute of Pathology, Department of Neuropathology, University of Debrecen Medical and Health Science Centre, Debrecen, Hungary

References

• [1] Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344–347 http://dx.doi.org/10.1056/NEJM197502132920706[Crossref]
• [2] Benveniste O. et al. International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord. 2010;20:414–421 http://dx.doi.org/10.1016/j.nmd.2010.03.014[Crossref]
• [3] Greenberg SA. Pathogenesis and therapy of inclusion body myositis. Curr Opin Neurol. 2012;25:630–639 http://dx.doi.org/10.1097/WCO.0b013e328357f211[WoS][Crossref]
• [4] Askanas V. et al. Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau. Presse Med. 2011;40(4 Pt 2):e219–235 http://dx.doi.org/10.1016/j.lpm.2010.11.024[Crossref]
• [5] Murnyák B., and Bodoki L. et al. Inclusion body myositis - pathomechanism and lessons from genetics 2013. (Cent Eur J Med. 2013 submitted for publication)
• [6] Greenberg SA. Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep. 2010;12:221–228 http://dx.doi.org/10.1007/s11926-010-0102-5[Crossref]
• [7] Váncsa A. et al. [Inclusion body myositis pathomechanism and therapy]. [Article in Hungarian]. Orv Hetil. 2008;149:1413–1418 http://dx.doi.org/10.1556/OH.2008.28070[Crossref]
• [8] Quick A. et al. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. Curr Rheumatol Rep. 2011;13:192–198 http://dx.doi.org/10.1007/s11926-011-0171-0[Crossref]
• [9] Kierdaszuk B. et al. Inclusion body myositis: therapeutic approaches. A case report. Neurol Neurochir Pol. 2011;45:68–73
• [10] Dziadzio M. et al. Common variable immunodeficiency with coexisting central nervous system sarcoidosis. Case report and literature review with implications for diagnosis and pathogenesis. Ideggyogy Sz 2011;64:405–408
• [11] Csonka T. et al. The diagnosis of herpes encephalitis- a case-based update. Ideggyogy Sz 2013 (in press)
• [12] Rider LG. et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2010 Apr;62(4):465–72. doi: 10.1002/acr.20035 http://dx.doi.org/10.1002/acr.20035[Crossref][WoS]
• [13] Kendall FP. Et al. Muscles: testing and function. 4th ed. Baltimore: Williams and Wilkins; 1993
• [14] Rider LG. et al. International Myositis Assessment and Clinical Studies Group, International Consensus On Preliminary Definitions of Improvement for Adult and Juvenile Myositis, Arthritis Rheum., 2004 Jul, 50(7):2281–2290 http://dx.doi.org/10.1002/art.20349[Crossref]
• [15] Cox FM. et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford). 2011;50:1153–1161 http://dx.doi.org/10.1093/rheumatology/ker001[Crossref][WoS]

Identifiers

DOI

10.2478/s11536-013-0250-x